Siemens Healthineers, a Germany-based medical device company and a subsidiary of multinational conglomerate Siemens, has announced plans to invest $428m (€396.06m) to open a new in-vitro diagnostics manufacturing facility in Shanghai, China.

The move comes after Siemens Healthineers split its Asia-Pacific operations into two in October 2022, “to allow both China and the rest of the region to achieve their full potential”. The Chinese operations are headed by Jerry Wang who had been in charge of the whole of Asia while the new Asia-Pacific Japan region is headed by Vy Tran, formerly Varian’s chief compliance and quality officer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The history of Siemens Healthineers can be traced back to the mid-18th century as an arm of the Siemens parent group. It has been known as Siemens Healthcare, Siemens Medical Solutions and Siemens Medical Systems. It was rebranded as Siemens Healthineers in 2016, and the companies it owns across the world have some 69,500 employees.